Inhibitors



GSK2838232

Cat. No.: HY-15884 1443460-91-0 CAS No.: Molecular Formula: $C_{48}H_{73}CIN_2O_6$

Molecular Weight: 809.56 HIV Target:

Pathway: Anti-infection

Storage: Powder -20°C 3 years

 $4^{\circ}C$ 2 years

-80°C In solvent 2 years

> -20°C 1 year

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: ≥ 50 mg/mL (61.76 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.2352 mL	6.1762 mL	12.3524 mL
	5 mM	0.2470 mL	1.2352 mL	2.4705 mL
	10 mM	0.1235 mL	0.6176 mL	1.2352 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (3.09 mM); Suspended solution; Need ultrasonic and warming
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.09 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.09 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GSK2838232 inhibit HIV reverse transcriptase activity across a broad panel of HIV-1 isolates, extracted from patent WO/2013090664A1, compound51.

REFERENCES

1]. Hatcher Mark Andrew, et al	. Preparation of betulin derivat	ives for the treatment of HIV. Fro	m PCT Int. Appl. (2013), WO 201309066	4 A1 20130620.
			ical applications. For research use	
	Tel: 609-228-6898 Address: 1 D	Fax: 609-228-5909 eer Park Dr, Suite Q, Monmou	E-mail: tech@MedChemExpress th Junction, NJ 08852, USA	s.com
		, ,		

Page 2 of 2 www.MedChemExpress.com